Orlistat plus hormone therapy for early endometrial cancer or atypical hyperplasia
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests adding orlistat to standard hormone therapy for people with early endometrial cancer or atypical hyperplasia who have not fully responded to initial hormone treatment. It aims to preserve fertility and avoid hysterectomy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with grade 1 or 2 endometrial cancer or atypical hyperplasia (a precancerous condition) confirmed by two pathologists.
- The cancer is limited to the inner lining of the uterus or has only very shallow invasion into the muscle (as seen on MRI or ultrasound).
- You are 45 years old or younger and wish to preserve your fertility.
- You have tried at least 3 months of high-dose hormone therapy (medroxyprogesterone or megestrol acetate) and it did not fully eliminate the lesion.
- Your tumor has low or weak progesterone receptor positivity (25% or less of cells, and staining intensity weak or none).
- Your body mass index (BMI) is 24 or higher, and you have no serious liver, kidney, or bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether medroxyprogesterone acetate (a progesterone hormone) plus atorvastatin (a cholesterol medicine) can treat early, limited problems in the womb lining—either atypical hyperplasia or early cancer (Grade 1) that has not spread into the muscle wall. It may help shrink or clear the abnormal tissue while supporting keeping fertility and the uterus.
This trial tests a combination of two hormone-blocking drugs (GnRHa plus letrozole) for women with early-stage, obesity-related endometrial cancer who haven't responded well to standard hormone therapy alone. The goal is to preserve the uterus and fertility while controlling the cancer.
This trial tests whether adding GnRH medicine and letrozole to standard progestin treatment can better control early, low-risk endometrial cancer or atypical hyperplasia in people who are not obese. It may help some patients avoid progression while keeping the uterus, especially for those wanting future fertility.
This study tests whether a three-month program that includes weight-loss medications and hormone therapy before surgery is better than surgery alone for women with early-stage endometrial cancer and severe obesity. The goal is to see if this approach improves surgical outcomes and overall health.
This study tests a new drug (PF-08634404) combined with chemotherapy for women with advanced or recurrent endometrial cancer that is MMR-proficient. The goal is to see if this combination works better than standard care.
This trial studies a weight-management approach plus a progesterone-releasing IUD (LNG-IUS) and megestrol to treat endometrial atypical hyperplasia, a high-risk precancer of the uterine lining. It may help shrink or control the abnormal cells while supporting fertility or keeping the uterus.
Hear when a new Endometrial Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.